Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro

Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):2002-2012. doi: 10.1080/21691401.2017.1408020. Epub 2017 Nov 27.

Abstract

Nanocapsules (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed. These nanocapsules are spherical, with an average hydrodynamic diameter of about 170 nm, and with negative zeta potential. NCS-DOX effectively co-delivered the selol and the doxorubicin into 4T1 cells and changed the intracellular distribution of DOX from the nuclei to the mitochondria. Moreover, a significantly increased cytotoxicity against 4T1 cells was observed, which is suggestive of additive or synergic effect of selol and doxorubicin. In conclusion, PVM/MA nanocapsules are suitable platforms to co-deliver drugs into cancer cells.

Keywords: Nanotechnology; cancer; cardiotoxicity; drug delivery systems; nanostructures.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Animals
  • Cell Line, Tumor
  • Cell Nucleus / metabolism
  • Cell Nucleus / pathology
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacokinetics
  • Doxorubicin* / pharmacology
  • Female
  • Mammary Neoplasms, Animal / drug therapy*
  • Mammary Neoplasms, Animal / metabolism
  • Mammary Neoplasms, Animal / pathology
  • Mice
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • NIH 3T3 Cells
  • Nanocapsules* / chemistry
  • Nanocapsules* / therapeutic use
  • Selenium Compounds* / chemistry
  • Selenium Compounds* / pharmacokinetics
  • Selenium Compounds* / pharmacology

Substances

  • Nanocapsules
  • Selenium Compounds
  • selol
  • Doxorubicin